Literature DB >> 19002787

Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

D Byrne1, C Daly, R Nicamhlaoibh, A Howlett, K Scanlon, M Clynes.   

Abstract

Chemotherapy can cure a number of human cancers but resistance (either intrinsic or acquired) remains a significant problem in many patients and in many types of solid tumour. Combination chemotherapy (using drugs with different cellular targets/mechanisms) was introduced in order to kill cells which had developed resistance to a specific drug, and to allow delivery of a greater total dose of anti-cancer chemicals by combining drugs with different side-effects (Pratt et al., 1994). Nearly all anti-cancer drugs kill tumour cells by activating an endogenous bio-chemical pathway for cell suicide, known as programmed cell death or apoptosis.

Entities:  

Year:  1998        PMID: 19002787      PMCID: PMC3449559          DOI: 10.1023/A:1008052401952

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  173 in total

Review 1.  Modulators of P-glycoprotein-associated multidrug resistance.

Authors:  W T Beck
Journal:  Cancer Treat Res       Date:  1991

Review 2.  The design of antisense RNA.

Authors:  G Sczakiel
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-08

3.  Modulation of multidrug resistance gene (mdr-1) with antisense oligodeoxynucleotides.

Authors:  C Liu; I A Qureshi; X Ding; Y Shan; Y Huang; Y Xie; M Ji
Journal:  Clin Sci (Lond)       Date:  1996-07       Impact factor: 6.124

Review 4.  Control of oncogene expression by antisense nucleic acids.

Authors:  C Hélène
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

Review 5.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

6.  Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides.

Authors:  X Liu; B G Pogo
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1996

7.  mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines.

Authors:  C Daly; S Coyle; S McBride; L O'Driscoll; N Daly; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1996       Impact factor: 2.058

8.  Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells.

Authors:  C A Stein; J L Tonkinson; L M Zhang; L Yakubov; J Gervasoni; R Taub; S A Rotenberg
Journal:  Biochemistry       Date:  1993-05-11       Impact factor: 3.162

9.  In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.

Authors:  C Cucco; B Calabretta
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

10.  Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.

Authors:  C Leonetti; I D'Agnano; F Lozupone; A Valentini; T Geiser; G Zon; B Calabretta; C Citro G; G Zupi
Journal:  J Natl Cancer Inst       Date:  1996-04-03       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.